Persistent reductions in OCS use in patients with severe, OCS dependent asthma treated with dupilumab: LIBERTY ASTHMA TRAVERSE study

Mark Gurnell; Christian  Domingo; Klaus F Rabe; Andrew Menzies-Gow; David Price; Guy  Brusselle; Michael E Wechsler; Changming  Xia; Michel  Djandji; Rebecca Gall; Juby A.  Jacob-Nara; Paul J.  Rowe; Yamo  Deniz; Shahid  Siddiqui

Persistent reductions in OCS use in patients with severe, OCS dependent asthma treated with dupilumab: LIBERTY ASTHMA TRAVERSE study

Mark Gurnell, Christian Domingo, Klaus F Rabe, Andrew Menzies-Gow, David Price, Guy Brusselle, Michael E Wechsler, Changming Xia, Michel Djandji, Rebecca Gall, Juby A. Jacob-Nara, Paul J. Rowe, Yamo Deniz, Shahid Siddiqui

Research output: Contribution to conference › Abstract › peer-review

Original language	English
Publication status	Accepted/In press - 8 Aug 2022
Event	World Allergy Congress 2022 - Hilton Bomonti Istanbul Hotel & Conference Center, Istanbul, Turkey Duration: 13 Oct 2022 → 15 Oct 2022 https://wacistanbul.com/

Conference

Conference	World Allergy Congress 2022
Abbreviated title	WAC 2022 Istanbul
Country/Territory	Turkey
City	Istanbul
Period	13/10/22 → 15/10/22
Internet address	https://wacistanbul.com/

Bibliographical note

Acknowledgments and funding sources
Data first presented at the American Thoracic Society - 118th International Conference (ATS 2022); San Francisco, CA, USA, May 13-18, 2022. Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ClinicalTrials.gov Identifiers: NCT02528214 (VENTURE)/NCT02134028 (TRAVERSE). Medical writing/editorial assistance was provided by Anthony Aggidis, PhD, of Excerpta Medica, and was funded by Sanofi and Regeneron Pharmaceuticals, Inc., according to the Good Publication Practice guideline.

Cite this

Gurnell, M., Domingo, C., Rabe, K. F., Menzies-Gow, A., Price, D., Brusselle, G., Wechsler, M. E., Xia, C., Djandji, M., Gall, R., Jacob-Nara, J. A., Rowe, P. J., Deniz, Y., & Siddiqui, S. (Accepted/In press). Persistent reductions in OCS use in patients with severe, OCS dependent asthma treated with dupilumab: LIBERTY ASTHMA TRAVERSE study . Abstract from World Allergy Congress 2022, Istanbul, Turkey.

Gurnell, M, Domingo, C, Rabe, KF, Menzies-Gow, A, Price, D, Brusselle, G, Wechsler, ME, Xia, C, Djandji, M, Gall, R, Jacob-Nara, JA, Rowe, PJ, Deniz, Y & Siddiqui, S 2022, 'Persistent reductions in OCS use in patients with severe, OCS dependent asthma treated with dupilumab: LIBERTY ASTHMA TRAVERSE study ', World Allergy Congress 2022, Istanbul, Turkey, 13/10/22 - 15/10/22.

@conference{04294e0085074316a83347bd25570354,

title = "Persistent reductions in OCS use in patients with severe, OCS dependent asthma treated with dupilumab: LIBERTY ASTHMA TRAVERSE study ",

author = "Mark Gurnell and Christian Domingo and Rabe, {Klaus F} and Andrew Menzies-Gow and David Price and Guy Brusselle and Wechsler, {Michael E} and Changming Xia and Michel Djandji and Rebecca Gall and Jacob-Nara, {Juby A.} and Rowe, {Paul J.} and Yamo Deniz and Shahid Siddiqui",

note = "Acknowledgments and funding sources Data first presented at the American Thoracic Society - 118th International Conference (ATS 2022); San Francisco, CA, USA, May 13-18, 2022. Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ClinicalTrials.gov Identifiers: NCT02528214 (VENTURE)/NCT02134028 (TRAVERSE). Medical writing/editorial assistance was provided by Anthony Aggidis, PhD, of Excerpta Medica, and was funded by Sanofi and Regeneron Pharmaceuticals, Inc., according to the Good Publication Practice guideline.; World Allergy Congress 2022, WAC 2022 Istanbul ; Conference date: 13-10-2022 Through 15-10-2022",

year = "2022",

month = aug,

day = "8",

language = "English",

url = "https://wacistanbul.com/",

}

TY - CONF

T1 - Persistent reductions in OCS use in patients with severe, OCS dependent asthma treated with dupilumab

T2 - World Allergy Congress 2022

AU - Gurnell, Mark

AU - Domingo, Christian

AU - Rabe, Klaus F

AU - Menzies-Gow, Andrew

AU - Price, David

AU - Brusselle, Guy

AU - Wechsler, Michael E

AU - Xia, Changming

AU - Djandji, Michel

AU - Gall, Rebecca

AU - Jacob-Nara, Juby A.

AU - Rowe, Paul J.

AU - Deniz, Yamo

AU - Siddiqui, Shahid

N1 - Acknowledgments and funding sources Data first presented at the American Thoracic Society - 118th International Conference (ATS 2022); San Francisco, CA, USA, May 13-18, 2022. Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ClinicalTrials.gov Identifiers: NCT02528214 (VENTURE)/NCT02134028 (TRAVERSE). Medical writing/editorial assistance was provided by Anthony Aggidis, PhD, of Excerpta Medica, and was funded by Sanofi and Regeneron Pharmaceuticals, Inc., according to the Good Publication Practice guideline.

PY - 2022/8/8

Y1 - 2022/8/8

M3 - Abstract

Y2 - 13 October 2022 through 15 October 2022

ER -